Joseph Gunnar & Co. has upgraded HeartBeam Inc. (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, reflecting regulatory progress and the company’s transition toward commercialization. The upgrade was highlighted in a recent article on AINewsBreaks.
The February 2026 report states, “We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection.” The report emphasizes a significant turning point for the company following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, which resolved an earlier regulatory setback and allowed HeartBeam to transition to commercial-stage status.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management.
The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com.
To view the full article, visit https://ibn.fm/NrrYt. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
This upgrade and price target increase underscore the market’s positive outlook on HeartBeam’s regulatory achievements and its potential to disrupt the cardiac monitoring space with its innovative technology.
